(Q37963986)

English

Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors

scientific article published on May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

based on heuristic

inferred from title

stem cell transplantation

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

author name string

David Telio

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Kim Fernandes

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Clement Ma

3

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Richard Tsang

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Armand Keating

5

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Michael Crump

6

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

John Kuruvilla

7

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Leukemia & Lymphoma

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

836-841

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggre

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2011.643404

21 January 2018

Identifiers

10.3109/10428194.2011.643404

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37963986&oldid=2124611438"